Rituximab combined with Bruton tyrosine kinase inhibitor to treat elderly diffuse large B-cell lymphoma patients: Two case reports

被引：1

作者：

Zhang, Cang-Jian ^{[1
]}

Zhao, Min-Lei ^{[1
]}

机构：

[1] Lishui Municipal Cent Hosp, Dept Hematol, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China

来源：

WORLD JOURNAL OF CLINICAL CASES | 2023年 / 11卷 / 29期

关键词：

Diffuse large B-cell lymphoma; Rituximab; Bruton tyrosine kinase inhibitors; Elderly patients; Case report; IBRUTINIB; CHEMOTHERAPY;

D O I：

10.12998/wjcc.v11.i29.7170

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUNDDiffuse large B-cell lymphoma (DLBCL) is a common aggressive non-Hodgkin's lymphoma (NHL), accounting for 30%-40% of adult NHLs. This report aims to explore the efficacy and safety of rituximab combined with Bruton tyrosine kinase inhibitors (BTKis) in the treatment of elderly patients with DLBCL.CASE SUMMARYThe clinical data of two elderly patients with DLBCL who received rituximab combined with BTKi in our hospital were retrospectively analyzed, and the literature was reviewed. The patients were treated with chemotherapy using the R-miniCHOP regimen for two courses. Then, they received rituximab in combination with BTKi.CONCLUSIONThe treatment experience in these cases demonstrates the potential efficacy of rituximab combined with BTKi to treat elderly DLBCL patients, thus providing a new treatment strategy.

引用

页码：7170 / 7178

页数：9

共 22 条

[1] Targeting BTK in CLL: Beyond Ibrutinib [J].

Bond, David A. ;

Woyach, Jennifer A. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (03) :197-205

[2] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[3] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[4] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[5] A Fast and Clean BTK Inhibitor [J].

Gabizon, Ronen ;

London, Nir .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) :5100-5101

[6] Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma [J].

Gang, Anne O. ;

Pedersen, Mette O. ;

Knudsen, Helle ;

Lauritzen, Anne F. ;

Pedersen, Michael ;

Nielsen, Signe L. ;

Brown, Peter ;

Hogdall, Estrid ;

Klausen, Tobias W. ;

Norgaard, Peter .

LEUKEMIA & LYMPHOMA, 2015, 56 (07) :2039-2046

[7] Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England [J].

Hounsome, L. ;

Eyre, T. A. ;

Ireland, R. ;

Hodson, A. ;

Walewska, R. ;

Ardeshna, K. ;

Chaganti, S. ;

McKay, P. ;

Davies, A. ;

Fox, C. P. ;

Kalakonda, N. ;

Fields, P. A. .

BRITISH JOURNAL OF CANCER, 2022, 126 (01) :134-143

[8] Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults [J].

Kavoosi, Mojgan ;

O'Reilly, Terry E. ;

Kavoosi, Mehran ;

Chai, Peng ;

Engel, Caroline ;

Korz, Walter ;

Gallen, Christopher C. ;

Lester, Robert M. .

TOXINS, 2020, 12 (08)

[9] Risk of infection associated with new therapies for lymphoproliferative syndromes [J].

Los-Arcos, Ibai ;

Aguilar-Company, Juan ;

Ruiz-Camps, Isabel .

MEDICINA CLINICA, 2020, 154 (03) :101-107

[10] Genetics of diffuse large B-cell lymphoma [J].

Pasqualucci, Laura ;

Dalla-Favera, Riccardo .

BLOOD, 2018, 131 (21) :2307-2319

← 1 2 3 →